Filed by Avantafile.com - Peptide Technologies Inc.

0001472375-19-000006.txt : 20190204 0001472375-19-000006.hdr.sgml : 20190204 20190201184718 ACCESSION NUMBER: 0001472375-19-000006 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190204 DATE AS OF CHANGE: 20190201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PEPTIDE TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001357878 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 980479983 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53230 FILM NUMBER: 19561255 BUSINESS ADDRESS: STREET 1: 5348 VEGAS DRIVE #177 CITY: LAS VEGAS STATE: NV ZIP: 89108 BUSINESS PHONE: (702) 805-7525 MAIL ADDRESS: STREET 1: 5348 VEGAS DRIVE #177 CITY: LAS VEGAS STATE: NV ZIP: 89108 FORMER COMPANY: FORMER CONFORMED NAME: Eternelle Skincare Products Inc. DATE OF NAME CHANGE: 20170621 FORMER COMPANY: FORMER CONFORMED NAME: PEPTIDE TECHNOLOGIES, INC. DATE OF NAME CHANGE: 20111007 FORMER COMPANY: FORMER CONFORMED NAME: CREENERGY Corp DATE OF NAME CHANGE: 20100818 10-Q 1 form10q.htm QUARTERLY RE PORT FOR THE PERIOD ENDED DECEMBER 31, 2018 Filed by Avantafile.com - Peptide Technologies Inc. - Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY RE PORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2018

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT

Commission File No. 000-53230

PEPTIDE TECHNOLOGIES, INC.

(Name of small business issuer as specified in its charter)

Nevada		98-0479983
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

5348 Vegas Drive #177

Las Vegas, NV 89108

(Address of principal executive offices)

(702) 948-8893

Registrant’s telephone number, including area code

Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days:

Yes [ ] No [X]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non–Accelerated filer	[ ]	Smaller reporting company	[X]
		Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act).

Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at January 30, 2019
Common stock, $0.001 par value		127,112,660

PEPTIDE TECHNOLOGIES, INC.

INDEX TO FORM 10-Q FILING

FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2018 AND 2017

TABLE OF CONTENTS

		PAGE
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	1
	Balance Sheets	2
	Statements of Operations	3
	Statements of Cash Flows	4
	Notes to Financial Statements	5
Item 2.	Management Discussion & Analysis of Financial Condition and Results of Operations	8
Item 3	Quantitative and Qualitative Disclosures About Market Risk	10
Item 4.	Controls and Procedures	10

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	12
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	12
Item 3.	Defaults Upon Senior Securities	12
Item 4.	Mining Safety Disclosures	12
Item 5	Other Information	12
Item 6.	Exhibits	12

CERTIFICATIONS

31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
32.1	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act
32.2	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

PART I

FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The accompanying interim financial statements have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders’ equity in conformity with accounting principles generally accepted in the United States of America. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2018. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included, and all such adjustments are of a normal recurring nature. Operating results for the three and nine months ended December 31, 2018 are not necessarily indicative of the results that can be expected for the year ending March 31, 2019.

PEPTIDE TECHNOLOGIES, INC.

BALANCE SHEETS

(UNAUDITED)

	December 31, 2018			March 31, 2018
ASSETS

Current Assets
Cash and cash equivalents	$	32,079		$	1,728
Total Current Assets		32,079			1,728

Website		9,322			13,341

Total Assets	$	41,401		$	15,069

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities
Accounts payable	$	42,455		$	37,870
Related-party advances		120,987			67,113
Accrued compensation		221,192			221,192
Other accrued liabilities		10,000			10,000
Total Current Liabilities		394,634			336,175

Stockholders’ Deficit
Common stock: $0.001 par value; 675,000,000 shares authorized; 127,112,660 shares issued and outstanding as of December 31, 2018 and March 31, 2018		127,113			127,113
Additional paid-in capital		776,963			731,963
Accumulated deficit		(1,257,309	)		(1,180,182	)
Total Stockholders’ Deficit		(353,233	)		(321,106	)
Total Liabilities and Stockholders’ Deficit	$	41,401		$	15,069

The accompanying notes are an integral part of these unaudited financial statements.

PEPTIDE TECHNOLOGIES, INC.

STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended						Nine Months Ended
	December 31,						December 31,
	2018			2017			2018			2017
Operating Expenses
General and administrative	$	51,990		$	10,254		$	75,379		$	35,501
Research and development		300			—			300			—
Total Operating Expenses		52,290			10,254			75,679			35,501

Operating Loss		(52,290	)		(10,254	)		(75,679	)		(35,501	)

Other Expense
Foreign currency loss		(1,455	)		(187	)		(1,448	)		(170	)
Net Loss	$	(53,745	)	$	(10,441	)	$	(77,127	)	$	(35,671	)

Basic and Diluted Loss per Common Share	$	—		$	—		$	—		$	—
Weighted Average Number of Common Shares Outstanding – Basic and Diluted		127,112,660			120,739,583			127,112,660			144,331,273

The accompanying notes are an integral part of these unaudited financial statements.

PEPTIDE TECHNOLOGIES, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Nine Months Ended
	December 31,
	2018			2017
Cash Flows From Operating Activities:
Net loss	$	(77,127	)	$	(35,671	)
Adjustments to reconcile net loss to cash flows used in operating activities:
Stock-based compensation		45,000			—
Depreciation and amortization		4,019			1,344
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		4,585			6,496
Net cash used for operating activities		(23,523	)		(27,831	)

Cash Flows From Investing Activities:
Website development		—			(16,000	)
Net cash used for investing activities		—			(16,000	)

Cash Flows From Financing Activities:
Related-party advances		53,874			47,598
Net cash provided by financing activities		53,874			47,598

Increase in cash and equivalents		30,351			3,767
Cash and cash equivalents, beginning of period		1,728			—
Cash and cash equivalents, end of period	$	32,079		$	3,767

The accompanying notes are an integral part of these unaudited financial statements.

PEPTIDE TECHNOLOGIES, INC.

NOTES TO FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2018 AND 2017

(Unaudited)

NOTE 1 – NATURE OF OPERATIONS

Peptide Technologies, Inc. (the “Company” or “Peptide”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.

The Company’s business is to develop and market skincare products. Its plan is to build a state-of-the-art online store with a direct marketing and sales funnel aimed at targeted channels, using internet, social media, and content marketing. The Company’s marketing approach uses vetted channels that encompass several steps to gauge performance data from marketing tests against other campaigns in real-time with the ability to modify content delivery to targeted consumers immediately. The Company will engage a team with proprietary algorithmic software to assist in making these marketing decisions. Management believes this will provide the Company a distinct advantage over other companies that outsource marketing and advertising efforts to third parties.

The skincare space is well-suited for direct-to-consumer sales, and there are several channels that the Company will leverage to introduce its unique branding and creative advertising assets. Creating brand visibility, along with the back-end support to process orders, is one of the Company’s key strengths over smaller competitors in the space. In addition, the Company will create a brand that allows visibility and awareness to be molded organically, thereby increasing the brand’s value quickly.

The Company has identified a cosmetic and skincare manufacturer and has agreed upon product formulations, the design and sourcing of packaging, and product costs. The Company does not intend to enter into a long-term master supply agreement with the manufacturer. Rather, orders will be placed through individual purchase orders as needed. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital to carry out its plan of operation and competition from existing consumer product companies.

The majority of manufacturing, distribution, marketing, and sales operations will be outsourced. However, strategic planning and development will be performed internally by the Company. This includes, but is not limited to, developing our catalog of products, developing proprietary skincare formulations, pricing our products, deciding which markets to target, deciding which influencers to engage in marketing campaigns, developing sales channels such as our e-commerce sites, determining which marketing initiatives to pursue, and selecting strategic partners and suppliers to advance our business plan.

Changes in Corporate Governance

In December 2018, Baxter Koehn resigned from his positions as Chief Financial Officer, Chairman of the Board of Directors, and Director of the Company. Irene Getty, who currently serves on the Company’s Board of Directors, has been appointed the Company’s Chief Financial Officer. Upon his resignation from the aforementioned positions, Baxter Koehn transferred 45,000,000 shares of common stock to Irene Getty. Baxter Koehn will continue to serve the Company as an office manager. See Note 7 for additional discussion.

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

Operating results for the three and nine months ended December 31, 2018 are not necessarily indicative of the results that may be expected for the year ending March 31, 2019. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2018 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2018 included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

NOTE 3 – GOING CONCERN

These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations and had an accumulated deficit of $1,257,309 as of December 31, 2018. The Company also had excess liabilities over assets of $353,233. These factors raise doubt about the Company’s ability to continue as a going concern.

Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.

These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.

NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue in the fourth quarter of this fiscal year.

Website

Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization for the three and nine months ended December 31, 2018 was $1,344 and $4,019, respectively. Amortization was $1,344 for both the three and nine months ended December 31, 2017.

Foreign Currency

The Company maintains a bank account denominated in Canadian dollars, and currency exchange rate fluctuations related to this account may impact the Company’s results of operations. Gains and losses on currency exchange rate fluctuations are recorded in other income/expense on the statements of operations.

Recent Accounting Pronouncements

The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

NOTE 5 – RELATED-PARTY TRANSACTIONS

The Company’s former Chief Financial Officer advanced $53,874 and $47,598 to the Company during the nine months ended December 31, 2018 and 2017, respectively, to pay for website development costs and operating expenses, as well as provide a limited amount of working capital. The advances are due on demand and carry no interest. The related-party advances totaled $120,987 and $67,113 as of December 31, 2018 and March 31, 2018, respectively.

See Note 7 for additional related party transactions.

NOTE 6 – COMMITMENTS AND CONTINGENCIES

The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.

NOTE 7 – STOCKHOLDERS’ DEFICIT

During the three months ended December 31, 2018, Baxter Koehn, who was the Chairman of the Board of Directors and Chief Financial Officer, transferred 45,000,000 shares of common stock with an estimated fair value of $45,000 to Irene Getty upon her appointment as the new Chief Financial Officer and his resignation from the Board of Directors. As Mr. Koehn was a significant shareholder owning more than 10% of the shares outstanding at the time, the Company recognized stock-based compensation expense of $45,000 related to this transfer of shares based on management’s estimate of fair value of the entity, net of liabilities. The stock-based compensation was recorded within general and administrative expense on the accompanying statement of operations.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In this Quarterly Report, “Company,” “our company,” “us,” and “our” refer to Peptide Technologies, Inc., unless the context requires otherwise.

Forward-Looking Statements

The following information contains certain forward-looking statements. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as “may,” “could,” “expect,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “possible,” “should,” “continue,” or similar terms, variations of those terms or the negative of those terms. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.

Business of Issuer

The business of Peptide Technologies, Inc. (the “Company” or “Peptide”) is to develop and market skincare products. The Company does business as Eternelle Skincare Products. Peptides are the latest innovation in skincare as science has proven that peptides can help manage wrinkles in skin and reverse the signs of aging. Using proprietary peptide blends, the Company has a number of skincare products that demonstrate strong efficacy in providing youthful, healthy skin and significant anti-aging benefits to both women and men.

Our skincare products address various skincare needs. These products include moisturizers and serums for the face and around the eyes.

Skin Brightener – A unique pigment clarifying serum that addresses uneven production of melanin. It synergistically targets areas of hyper pigmentation.

Vitamin C Peptide – Plant-based collagen serum created to resist damage from aging, sun damage, and environmental exposure.

Skin Moisturizer – A super fruit, antioxidant rich crème that contains age defying peptides and vitamin C that significantly minimizes visible signs of aging.

Peptide Eye Gel Crème - A fast-penetrating, therapeutic treatment crème formulated with potent peptides that significantly minimizes visible signs of aging by moisturizing and protecting against free radical damage.

Eye Serum - A unique peptide-derived microcirculation treatment that absorbs into the skin, addressing areas that lack circulation.

Our Company has developed its proprietary skincare formulations, and we will use internationally recognized experts in the manufacturing of specialized, professional quality products that meet the demands of day and resort spa, medical spa, and eco spa markets.

The Company has identified a cosmetic and skincare manufacturer and has agreed upon product formulations, the design and sourcing of packaging, and product costs. The Company does not intend to enter into a long-term master supply agreement with the manufacturer. Rather, orders will be placed through individual purchase orders as needed. With profound knowledge and expertise in cosmetic chemistry and professional skincare, this manufacturer has established itself as a leader in cutting edge formulations and product innovation in the field of skincare.

This manufacturer offers custom product formulation and manufacturing, allowing our Company to develop proprietary blends in order to privately brand our collection.

This supplier manufactures products in accordance with Good Manufacturing Procedures (GMP). It also follows the recommendations of the United States Food and Drug Administration and Health Canada and also adheres to the Quality Assurance Guidelines of the Cosmetic, Toiletry, and Fragrance Association. These guidelines enable us to guarantee the consistency and quality of our products from batch to batch. The manufacturer performs toxicity, microbiological, temperature, and stability tests on all formulations. They do not test on animals, and they select all botanicals for freshness, purity of source, quality, and potency. Every product will be researched and tested by the supplier’s manufacturing team before it is approved for sale.

We expect to launch our products and begin recognizing revenue in the fourth quarter of this fiscal year.

Financial Results and Trends

Results of Operations for the Nine Months Ended December 31, 2018 and 2017

At present, the Company has no revenue. Net loss increased from $35,671 for the nine months ended December 31, 2017 to $77,127 for the nine months ended December 31, 2018 primarily due to stock-based compensation of $45,000 related to the transfer of 45,000,000 shares of common stock to the Company’s new Chief Financial Officer. Management assessed the estimated fair value of the shares, after considering the significant indebtedness and limited operating history.

Liquidity and Capital Resources

The Company requires significant cash to launch its business and reduce its payables. The Company’s primary sources of liquidity and capital resources have been related-party advances, which are not sufficient prospectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. We are actively seeking to raise additional debt and/or equity capital to add new products and/or services to commence material operations. If the Company is unable to raise additional capital in the near future or meet financing requirements, the Company may need to curtail or alter its plan of operation.

Cash Flow

The following table summarizes, for the periods indicated, selected items in our condensed Statements of Cash Flows:

	Nine Months Ended
	December 31,
	2018			2017
Net cash (used in) provided by:
Operating activities	$	(23,523	)	$	(27,831	)
Investing activities	$	—		$	(16,000	)
Financing activities	$	53,874		$	47,598

Operating Activities

Cash used in operating activities was $23,523 and $27,831 for the nine months ended December 31, 2018 and 2017, respectively. The decrease in cash used in operating activities was primarily due to a lower cash expenses.

Investing Activities

Cash used in investing activities was $0 and $16,000 for the nine months ended December 31, 2018 and 2017, respectively. The decrease in cash used in investing activities was primarily due to one-time website development costs incurred in the prior year.

Financing Activities

Cash provided by financing activities was $53,874 and $47,598 for the nine months ended December 31, 2018 and 2017, respectively. The increase in cash provided by financing activities was primarily due to higher related-party advances.

Off-Balance Sheet Arrangements

None.

WHERE YOU CAN FIND MORE INFORMATION

You are advised to read this Quarterly Report on Form 10-Q in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Registration Statement on Form 10-12G, Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We had no material changes in market risk from those described in “Item 2—Quantitative and Qualitative Disclosures about Market Risk” of our Annual Report on Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

This report includes the certification of our Chief Executive Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations revered to in those certifications.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s (the “SEC”) rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are being designed to provide reasonable assurance that the controls and procedures would meet their objectives.

As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer need to carry out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer has not yet concluded that our disclosure controls and procedures were effective as of December 31, 2018.

Management’s Report on Internal Control over Financial Reporting

Our Chief Executive Officer and the Chief Financial Officer are responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of our internal control over financial reporting. Internal control over financial reporting (as defined in Rules 13a-15(f) and 15d(f) under the Exchange Act) is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. GAAP. Internal control over financial reporting includes those policies and procedures that (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets, (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (c) provide reasonable assurance that receipts and expenditures are being made only in accordance with appropriate authorization of management and the Board of Directors, and (d) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the financial statements.

In connection with the preparation of our Annual Report on Form 10-K for the year ended March 31, 2019, our Chief Executive Officer and Chief Financial Officer will evaluate the effectiveness of our internal control over financial reporting as of March 31, 2019.

Inherent Limitations on Internal Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the control system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Limitations inherent in any control system include the following:

Judgments in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes;
Controls can be circumvented by individuals, acting alone or in collusion with others, or by management override;
The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions;
Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with associated policies or procedures; and
The design of a control system must reflect the fact that resources are constrained, and the benefits of controls must be considered relative to their costs.

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As of December 31, 2018, the Company is not involved in any material litigation.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS SECURITIES

During the nine months ended December 31, 2018, Peptide did not sell any unregistered equity securities.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINING SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

There is no information with respect to which information is not otherwise called for by this form.

ITEM 6. EXHIBITS

Exhibits

3.0		Articles of Incorporation. Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

3.1		Amended Articles of Incorporation. Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

3.2		Amended Articles of Incorporation. Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

3.3		Corporate Bylaws. Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

10.1		Advance from Baxter Koehn to Peptide Technologies, Inc. Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act

31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act

32.1		Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

32.2		Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Registrant	Peptide Technologies, Inc.

Date: February 1, 2019	By:	/s/ Bruce Sellars
	Bruce Sellars
	Chief Executive Officer

EX-31.1 2 exhibit31-1.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies Inc. - Exhibit 31.1

Exhibit 31.1

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 for the period ending December 31, 2018

I, Bruce Sellars, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Peptide Technologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and will have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Registrant	Peptide Technologies, Inc.

Date: February 1, 2019	By:	/s/ Bruce Sellars
	Bruce Sellars
	Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 exhibit31-2.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies Inc. - Exhibit 31.2

Exhibit 31.2

I, Irene Getty, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Peptide Technologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and will have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Registrant	Peptide Technologies, Inc.

Date: February 1, 2019	By:	/s/ Irene Getty
	Irene Getty
	Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 exhibit32-1.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies Inc. - Exhibit 32.1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Peptide Technologies, Inc. (the ‘Company’) on Form 10-Q for the period ending December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the ‘Report’), I, Bruce Sellars, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)		The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Registrant	Peptide Technologies, Inc.

Date: February 1, 2019	By:	/s/ Bruce Sellars
	Bruce Sellars
	Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 exhibit32-2.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies Inc. - Exhibit 32.2

Exhibit 32.2

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Peptide Technologies, Inc. (the ‘Company’) on Form 10-Q for the period ending December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the ‘Report’), I, Irene Getty, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)		The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Registrant	Peptide Technologies, Inc.

Date: February 1, 2019	By:	/s/ Irene Getty
	Irene Getty
	Chief Financial Officer (Principal Financial Officer)

GRAPHIC 6 logo.gif begin 644 logo.gif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pept-20181231.xml INSTANCE DOCUMENT 0001357878 2018-04-01 2018-12-31 0001357878 2019-01-30 0001357878 2018-12-31 0001357878 2018-03-31 0001357878 2017-04-01 2017-12-31 0001357878 2017-12-31 0001357878 us-gaap:ChiefFinancialOfficerMember 2018-12-31 0001357878 us-gaap:ChiefFinancialOfficerMember 2017-12-31 0001357878 2017-03-31 0001357878 2018-10-01 2018-12-31 0001357878 2017-10-01 2017-12-31 0001357878 us-gaap:StockCompensationPlanMember 2018-10-01 2018-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares PEPTIDE TECHNOLOGIES, INC. 0001357878 10-Q 2018-12-31 false --03-31 Yes Non-accelerated Filer 2018 127112660

120987

67113

53874

47598

2005-11-18

P3Y

4019

1344

0.001

675000000

127112660

true false

41401

15069

-353233

-321106

-1257309

-1180182

776963

731963

127113

9322

13341

32079

1728

41401

15069

42455

37870

221192

10000

394634

336175

127112660

144331273

127112660

120739583

-77127

-35671

-53745

-10441

-1448

-170

-1455

-187

-75679

-35501

-52290

-10254

75679

35501

52290

10254

300

75379

35501

51990

10254

45000

77127

35671

4585

6496

23523

27831

45000

4019

1344

16000

-16000

53874

47598

53874

47598

30351

3767

32079

1728

3767

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS   The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.   Operating results for the three and nine months ended December 31, 2018 are not necessarily indicative of the results that may be expected for the year ending March 31, 2019. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2018 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2018 included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

NOTE 3 – GOING CONCERN   These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations and had an accumulated deficit of $1,257,309 as of December 31, 2018. The Company also had excess liabilities over assets of $353,233. These factors raise doubt about the Company’s ability to continue as a going concern.   Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.   These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.

NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES   Revenue Recognition   Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue in the fourth quarter of this fiscal year.   Website   Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization for the three and nine months ended December 31, 2018 was $1,344 and $4,019, respectively. Amortization was $1,344 for both the three and nine months ended December 31, 2017.   Foreign Currency   The Company maintains a bank account denominated in Canadian dollars, and currency exchange rate fluctuations related to this account may impact the Company’s results of operations. Gains and losses on currency exchange rate fluctuations are recorded in other income/expense on the statements of operations.   Recent Accounting Pronouncements   The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

Revenue Recognition   Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue in the fourth quarter of this fiscal year.

Website   Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization for the three and nine months ended December 31, 2018 was $1,344 and $4,019, respectively. Amortization was $1,344 for both the three and nine months ended December 31, 2017.

Foreign Currency   The Company maintains a bank account denominated in Canadian dollars, and currency exchange rate fluctuations related to this account may impact the Company’s results of operations. Gains and losses on currency exchange rate fluctuations are recorded in other income/expense on the statements of operations.

Recent Accounting Pronouncements   The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

NOTE 1 – NATURE OF OPERATIONS   Peptide Technologies, Inc. (the “Company” or “Peptide”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.   The Company’s business is to develop and market skincare products. Its plan is to build a state-of-the-art online store with a direct marketing and sales funnel aimed at targeted channels, using internet, social media, and content marketing. The Company’s marketing approach uses vetted channels that encompass several steps to gauge performance data from marketing tests against other campaigns in real-time with the ability to modify content delivery to targeted consumers immediately. The Company will engage a team with proprietary algorithmic software to assist in making these marketing decisions. Management believes this will provide the Company a distinct advantage over other companies that outsource marketing and advertising efforts to third parties.   The skincare space is well-suited for direct-to-consumer sales, and there are several channels that the Company will leverage to introduce its unique branding and creative advertising assets. Creating brand visibility, along with the back-end support to process orders, is one of the Company’s key strengths over smaller competitors in the space. In addition, the Company will create a brand that allows visibility and awareness to be molded organically, thereby increasing the brand’s value quickly.   The Company has identified a cosmetic and skincare manufacturer and has agreed upon product formulations, the design and sourcing of packaging, and product costs. The Company does not intend to enter into a long-term master supply agreement with the manufacturer. Rather, orders will be placed through individual purchase orders as needed. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital to carry out its plan of operation and competition from existing consumer product companies.   The majority of manufacturing, distribution, marketing, and sales operations will be outsourced. However, strategic planning and development will be performed internally by the Company. This includes, but is not limited to, developing our catalog of products, developing proprietary skincare formulations, pricing our products, deciding which markets to target, deciding which influencers to engage in marketing campaigns, developing sales channels such as our e-commerce sites, determining which marketing initiatives to pursue, and selecting strategic partners and suppliers to advance our business plan.   Changes in Corporate Governance   In December 2018, Baxter Koehn resigned from his positions as Chief Financial Officer, Chairman of the Board of Directors, and Director of the Company. Irene Getty, who currently serves on the Company’s Board of Directors, has been appointed the Company’s Chief Financial Officer. Upon his resignation from the aforementioned positions, Baxter Koehn transferred 45,000,000 shares of common stock to Irene Getty. Baxter Koehn will continue to serve the Company as an office manager. See Note 7 for additional discussion.

NOTE 5 – RELATED-PARTY TRANSACTIONS   The Company’s former Chief Financial Officer advanced $53,874 and $47,598 to the Company during the nine months ended December 31, 2018 and 2017, respectively, to pay for website development costs and operating expenses, as well as provide a limited amount of working capital. The advances are due on demand and carry no interest. The related-party advances totaled $120,987 and $67,113 as of December 31, 2018 and March 31, 2018, respectively.   See Note 7 for additional related party transactions.

NOTE 7 – STOCKHOLDERS’ DEFICIT   During the three months ended December 31, 2018, Baxter Koehn, who was the Chairman of the Board of Directors and Chief Financial Officer, transferred 45,000,000 shares of common stock with an estimated fair value of $45,000 to Irene Getty upon her appointment as the new Chief Financial Officer and his resignation from the Board of Directors. As Mr. Koehn was a significant shareholder owning more than 10% of the shares outstanding at the time, the Company recognized stock-based compensation expense of $45,000 related to this transfer of shares based on management’s estimate of fair value of the entity, net of liabilities. The stock-based compensation was recorded within general and administrative expense on the accompanying statement of operations.

45000000

NOTE 6 – COMMITMENTS AND CONTINGENCIES   The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.

EX-101.SCH 8 pept-20181231.xsd SCHEMA DOCUMENT 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Nature Of Operations link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis Of Presentation Of Interim Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders Deficit link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Nature Of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stockholders Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 pept-20181231_cal.xml CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 pept-20181231_def.xml DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 pept-20181231_lab.xml LABELS LINKBASE DOCUMENT Related Party [Axis] Chief Financial Officer [Member] Award Type [Axis] Stock Compensation [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Amendment Description Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Is Entity Emerging Growth Company? Elected Not To Use the Extended Transition Period Entity Filer Category Entity Small Business Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash and cash equivalents Total Current Assets Website Total Assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable Related-party advances Accrued compensation Other accrued liabilities Total Current Liabilities Commitments and Contingencies Stockholders' Deficit Common stock: $0.001 par value; 675,000,000 shares authorized; 127,112,660 shares issued and outstanding as of December 31, 2018 and March 31, 2018 Additional paid-in capital Accumulated deficit Total Stockholders' Deficit Total Liabilities and Stockholders' Deficit Common stock par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating Expenses General and administrative Research and development Total Operating Expenses Operating Loss Other Expense Foreign currency loss Net Loss Basic and Diluted Loss per Common Share Weighted Average Number of Common Shares Outstanding - Basic and Diluted Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net loss Adjustments to reconcile net loss to cash flows used in operating activities Stock-based compensation Depreciation and amortization Changes in operating assets and liabilities: Accounts payable and accrued liabilities Net cash used for operating activities Cash Flows From Investing Activities: Website development Net cash used for investing activities Cash Flows From Financing Activities: Related-party advances Net cash provided by financing activities (Decrease) increase in cash and equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature Of Operations Accounting Policies [Abstract] Basis Of Presentation Of Interim Financial Statements Going Concern Significant Accounting Policies Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stockholders Deficit Revenue Recognition Website Foreign Currency Recent Accounting Pronouncements Date of Incorporation Accumulated deficit Total Stockholders' Deficit Website Estimated Useful Life Amortization Expense, Website Statement [Table] Statement [Line Items] Related party advances Shares Transferred General and administrative expense Operating Expenses [Default Label] Operating Income (Loss) Net Income (Loss) Attributable to Parent Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Cash Provided by (Used in) Operating Activities Payments for Software Net Cash Provided by (Used in) Investing Activities Increase (Decrease) in Notes Payable, Related Parties Net Cash Provided by (Used in) Financing Activities Property, Plant and Equipment, Preproduction Design and Development Costs [Policy Text Block] EX-101.PRE 12 pept-20181231_pre.xml PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Dec. 31, 2018	Jan. 30, 2019
Document And Entity Information
Entity Registrant Name	PEPTIDE TECHNOLOGIES, INC.
Entity Central Index Key	0001357878
Document Type	10-Q
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity's Reporting Status Current?	Yes
Is Entity Emerging Growth Company?	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Common Stock, Shares Outstanding		127,112,660
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018

XML 14 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Current Assets
Cash and cash equivalents	$ 32,079	$ 1,728
Total Current Assets	32,079	1,728
Website	9,322	13,341
Total Assets	41,401	15,069
Current Liabilities
Accounts payable	42,455	37,870
Related-party advances	120,987	67,113
Accrued compensation	221,192	221,192
Other accrued liabilities	10,000	10,000
Total Current Liabilities	394,634	336,175
Stockholders' Deficit
Common stock: $0.001 par value; 675,000,000 shares authorized; 127,112,660 shares issued and outstanding as of December 31, 2018 and March 31, 2018	127,113	127,113
Additional paid-in capital	776,963	731,963
Accumulated deficit	(1,257,309)	(1,180,182)
Total Stockholders' Deficit	(353,233)	(321,106)
Total Liabilities and Stockholders' Deficit	$ 41,401	$ 15,069

XML 15 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Mar. 31, 2018
Statement of Financial Position [Abstract]
Common stock par value	$ 0.001	$ 0.001
Common stock, shares authorized	675,000,000	675,000,000
Common stock, shares issued	127,112,660	127,112,660
Common stock, shares outstanding	127,112,660	127,112,660

XML 16 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Operating Expenses
General and administrative	$ 51,990	$ 10,254	$ 75,379	$ 35,501
Research and development	300		300
Total Operating Expenses	52,290	10,254	75,679	35,501
Operating Loss	(52,290)	(10,254)	(75,679)	(35,501)
Other Expense
Foreign currency loss	(1,455)	(187)	(1,448)	(170)
Net Loss	$ (53,745)	$ (10,441)	$ (77,127)	$ (35,671)
Basic and Diluted Loss per Common Share
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	127,112,660	120,739,583	127,112,660	144,331,273

XML 17 R5.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows - USD ($)	9 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From Operating Activities:
Net loss	$ (77,127)	$ (35,671)
Adjustments to reconcile net loss to cash flows used in operating activities
Stock-based compensation	45,000
Depreciation and amortization	4,019	1,344
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	4,585	6,496
Net cash used for operating activities	(23,523)	(27,831)
Cash Flows From Investing Activities:
Website development		(16,000)
Net cash used for investing activities		(16,000)
Cash Flows From Financing Activities:
Related-party advances	53,874	47,598
Net cash provided by financing activities	53,874	47,598
(Decrease) increase in cash and equivalents	30,351	3,767
Cash and cash equivalents, beginning of period	1,728
Cash and cash equivalents, end of period	$ 32,079	$ 3,767

XML 18 R6.htm IDEA: XBRL DOCUMENT

Nature Of Operations

9 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature Of Operations

NOTE 1 – NATURE OF OPERATIONS

Peptide Technologies, Inc. (the “Company” or “Peptide”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.

Changes in Corporate Governance

XML 19 R7.htm IDEA: XBRL DOCUMENT

Basis Of Presentation Of Interim Financial Statements

9 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis Of Presentation Of Interim Financial Statements

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

XML 20 R8.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

NOTE 3 – GOING CONCERN

XML 21 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Significant Accounting Policies

NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Website

Foreign Currency

Recent Accounting Pronouncements

XML 22 R10.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Dec. 31, 2018

Related Party Transactions

NOTE 5 – RELATED-PARTY TRANSACTIONS

See Note 7 for additional related party transactions.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Commitments And Contingencies

9 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies

NOTE 6 – COMMITMENTS AND CONTINGENCIES

The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.

XML 24 R12.htm IDEA: XBRL DOCUMENT

Stockholders Deficit

9 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stockholders Deficit

NOTE 7 – STOCKHOLDERS’ DEFICIT

XML 25 R13.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2018
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition Revenue will be recognized on a gross basis upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management will assess the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue in the fourth quarter of this fiscal year.
Website	Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization for the three and nine months ended December 31, 2018 was $1,344 and $4,019, respectively. Amortization was $1,344 for both the three and nine months ended December 31, 2017.
Foreign Currency	Foreign Currency The Company maintains a bank account denominated in Canadian dollars, and currency exchange rate fluctuations related to this account may impact the Company’s results of operations. Gains and losses on currency exchange rate fluctuations are recorded in other income/expense on the statements of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

XML 26 R14.htm IDEA: XBRL DOCUMENT

Nature Of Operations (Details Narrative)	9 Months Ended
Nature Of Operations (Details Narrative)	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of Incorporation	Nov. 18, 2005

XML 27 R15.htm IDEA: XBRL DOCUMENT

Going Concern (Details Narrative) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 1,257,309	$ 1,180,182
Total Stockholders' Deficit	$ 353,233	$ 321,106

XML 28 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Website Estimated Useful Life			3 years
Amortization Expense, Website	$ 1,344	$ 1,344	$ 4,019	$ 1,344

XML 29 R17.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Related party advances	$ 120,987	$ 67,113
Chief Financial Officer [Member]
Related party advances	$ 53,874		$ 47,598

XML 30 R18.htm IDEA: XBRL DOCUMENT

Stockholders Deficit (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Stockholders Deficit (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Stock-based compensation			$ 45,000
General and administrative expense	$ 51,990	$ 10,254	$ 75,379	$ 35,501
Stock Compensation [Member]
Shares Transferred	45,000,000
Stock-based compensation	$ 45,000
General and administrative expense	$ 45,000

EXCEL 31 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 32 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 33 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 12 64 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://eternelleskincare.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://eternelleskincare.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://eternelleskincare.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://eternelleskincare.com/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statements of Cash Flows Sheet http://eternelleskincare.com/role/StatementsOfCashFlows Statements of Cash Flows Statements 5 false false R6.htm 00000006 - Disclosure - Nature Of Operations Sheet http://eternelleskincare.com/role/NatureOfOperations Nature Of Operations Notes 6 false false R7.htm 00000007 - Disclosure - Basis Of Presentation Of Interim Financial Statements Sheet http://eternelleskincare.com/role/BasisOfPresentationOfInterimFinancialStatements Basis Of Presentation Of Interim Financial Statements Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://eternelleskincare.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://eternelleskincare.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://eternelleskincare.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - Commitments And Contingencies Sheet http://eternelleskincare.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders Deficit Sheet http://eternelleskincare.com/role/StockholdersDeficit Stockholders Deficit Notes 12 false false R13.htm 00000013 - Disclosure - Significant Accounting Policies (Policies) Sheet http://eternelleskincare.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://eternelleskincare.com/role/SignificantAccountingPolicies 13 false false R14.htm 00000014 - Disclosure - Nature Of Operations (Details Narrative) Sheet http://eternelleskincare.com/role/NatureOfOperationsDetailsNarrative Nature Of Operations (Details Narrative) Details http://eternelleskincare.com/role/NatureOfOperations 14 false false R15.htm 00000015 - Disclosure - Going Concern (Details Narrative) Sheet http://eternelleskincare.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://eternelleskincare.com/role/GoingConcern 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://eternelleskincare.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://eternelleskincare.com/role/SignificantAccountingPoliciesPolicies 16 false false R17.htm 00000017 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://eternelleskincare.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://eternelleskincare.com/role/RelatedPartyTransactions 17 false false R18.htm 00000018 - Disclosure - Stockholders Deficit (Details Narrative) Sheet http://eternelleskincare.com/role/StockholdersDeficitDetailsNarrative Stockholders Deficit (Details Narrative) Details http://eternelleskincare.com/role/StockholdersDeficit 18 false false All Reports Book All Reports pept-20181231.xml pept-20181231.xsd pept-20181231_cal.xml pept-20181231_def.xml pept-20181231_lab.xml pept-20181231_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 37 0001472375-19-000006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001472375-19-000006-xbrl.zip M4$L#!!0 ( N604X8S_H;81P !.O 1 <&5P="TR,#$X,3(S,2YX M;6SM7>ES&S>R__ZJWO^ TN:EDBI2XB&*.NQLT13ML&)36E%^N_FT-9P!243# M&68P0XG[UV]W YC!\+XDVY%3E<0F 72CT<>O&P??_/UIY+,)CZ0(@[='Y>/2 M$>.!&WHB&+P]^MPM-KK-=ON(_?V7__V?-T^]R!>7^%\&O0)Y^23%VZ-A'(\O M3TX>'Q^/'ZO'830XJ91*Y9-_??K8=8=\Y!1%(&,G6+X&%1O_+%Q<4) M?6N:SK5$XH9&]02_[CDR&QD97-%^CA/XUHO3#G;CVHGZ,M=4+&QZIIH*T]3C M,^TD=X\'X>0$OH#VY?-BJ5RLEDWSB/>7LGQV M^:AD*&IY5R?=7\5 O3(9'% M@>.,TPY]1_:HL?YB 3/P313Z7"[L0]\LZ!2$09",%O/EQ=%)/!WS$VA4A%8\ M$F[:;WVG? ?@ 3]>S!U]LX [-TR".)HN7A+])7:KY[O)*)XG Q\NH'#;NKU/ MV_*81P'W05(/(G"=B!^[X8@ZE2O0!>R(P3]O4'4O)1G('>\STOK+(>G"F(_C MHNEP_"2](_TUSO#MD12CL0\J?&*&4F;IAD',GV(FO+='[Z-PI-@\!4[CD/Y< MKA0S^FDW'L0BGJ:?II\+#[_I"QXQXI+G5LJ(K]G^[>B7$IA[M58_KY^_.9GM MG)$[64A/4QO#*H?>/!=@KE%\[<3\EVPZ9J3LN[EN//"R3C3OC+R7ZV(^SS%@ M/M0B72[GAKSI XT+4H?2-R9;Y0SC7[()I"3T-P<5TK>I@):09C3IF814JG[C M0J()/(^0M%NK6VZM_DUJ5C+R;(3._X8,0M":1?><#,T]@7KH@5K\P3T%(E M!7IJEW?1$TC'C:&!?#>UOVD\"7GTB^FS0AQO3A92MKD^6_73,\\Y_Q8Q?VOE_ MA6::!$+ISN?N]9P"C+@CDXC_HDM]E]#&#&:^RI/ T9:,WQTZ$9=+26@A4*.= M:0!_MTOH>&("FC-:A&]YD$X DBRANQZN#SQ)M@5Y'CMP.//_W&IQM3M]W-TM%LAFZ!A MH]O8F K8[3_4^';W1DAVVE)5N/+YMYTM'L\DUX%L/6[SWG<'&9/J.+[FB MD!O 'KF91!%^+*3K^+]S)]IV+D6#WU:-MD !5,L[/@ZC6 2#;NS$B=R8ZN]H M+.M&FZ?Z7O@\:@)#@S#:7.DZ85!T7)?[:.[<8S2*33XW["(UR03R'C[9?)KX MY[R*S(RT0+#A:!0&%!.5I[Q)8H34N >7HSM3;F;H)>@+[6"9QUTQ A5Z>]3N MO >CJ-3+Y#D#Z51?@I7-"P&KV*U5S^NGS\_N-G6+5>R>UFL7Y]NP MFZEH.W##"/P"04-T1C?]W$=;&&.I5BR7B^5<[%DW_*S\8/(BYA_%A'OM "QE M('H^;TC)X\^2]Q/_H^AO$8RKOV="V63D66X:(W28_R%.D?%3 M\;B:WO[<+:KFK_0@U=/3E^-N41WBZ^%N4?9^:.[F0YG"/-N%Q7]4%P5%:Z19 M85AA"MS%383X@'O_[_@)AUX4N3:.0;=+XF/IN(3)WA8D#\;E@NCT(EPJ&HTD M'H:1^ \@HXUDN(2SLWJM1/\LY&Z6U-Y;.\LX2K@-6'*CS!-IC7@T M /(?HO Q'F)9S0DV3Y6LE'/%<+,B_RBWLUI$Y#%OK4X5RK71VL3M;AY-/L5JK5JI6UG(XXNNE4*Q6RN72V3;$ M[WCL@-IZ+2<*0*=DPX7XGU 6<,W[6-_=61+E2JU>+5FKLI[6H;C;0%3E\CFT MK.S#7/[LXLS1GR?![<;%>,/5J>1Z&SB0+>DNSPQEA^]L,Q?52F63[!-I'(*C#>12K9Z6=V5) M?;%G1:I:*=7M=-<>
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end